| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/09/2001 | WO2001056561A1 Preventives for viral infection |
| 08/09/2001 | WO2001056560A1 Substituted amino acids as neutral sphingomyelinase inhibitors |
| 08/09/2001 | WO2001056559A1 Aqueous solution for treating degenerative or autoimmune diseases and as immunomodulatory agent |
| 08/09/2001 | WO2001056558A1 Polycyclic dianthraquinones as anti-cancer and anti-angiogenic agents |
| 08/09/2001 | WO2001056557A2 Compositions useful as inhibitors of erk |
| 08/09/2001 | WO2001056556A2 Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders |
| 08/09/2001 | WO2001056555A2 Use of cox-2 inhibitors for the treatment of constipation |
| 08/09/2001 | WO2001056554A2 Use of retinoid-type compounds as antibacterial agents |
| 08/09/2001 | WO2001056553A2 Pharmaceutically active aromatic guanylhydrazones |
| 08/09/2001 | WO2001056552A2 Farnesyl protein transferase inhibitors for treating breast cancer |
| 08/09/2001 | WO2001056551A2 Method and formulation for treatment of vasoconstriction |
| 08/09/2001 | WO2001056549A1 Continuous method for preparing pharmaceutical granules |
| 08/09/2001 | WO2001056548A2 Liposomes composition produced by a dehydration-rehydration process |
| 08/09/2001 | WO2001056547A2 Preparation of aqueous clear solution dosage forms with bile acids |
| 08/09/2001 | WO2001056544A2 Shell-and-core dosage form approaching zero-order drug release |
| 08/09/2001 | WO2001056541A1 Cosmetic preparations containing waltheria indica extracts |
| 08/09/2001 | WO2001056536A1 Compact hairspray product consisting of hairspray concentrate, container and fine spray pump with pre-pressurization |
| 08/09/2001 | WO2001056406A1 Improved pediatric formula and methods for providing nutrition and improving tolerance |
| 08/09/2001 | WO2001056405A2 A method for maintaining or improving the synthesis of mucins |
| 08/09/2001 | WO2001056404A1 Low molecular weight polymannuronate |
| 08/09/2001 | WO2001056382A1 Novel diphenylethylene compounds |
| 08/09/2001 | WO2001056358A2 Enhanced propertied pesticides |
| 08/09/2001 | WO2001032596A8 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 08/09/2001 | WO2001019814A3 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 08/09/2001 | WO2001019788A3 BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| 08/09/2001 | WO2001019374A3 Glucosamine and egg reducing inflammation |
| 08/09/2001 | WO2001019349A3 Extended release formulation of etodolac |
| 08/09/2001 | WO2001019342A3 Pharmaceutical formulation of fluticasone propionate |
| 08/09/2001 | WO2001019337A3 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| 08/09/2001 | WO2001018004A3 PYRAZOLO[4,3-d]PYRIMIDINES |
| 08/09/2001 | WO2001016312A3 Nucleic acid based modulators of gene expression |
| 08/09/2001 | WO2001014376A8 Novel spiro compounds |
| 08/09/2001 | WO2001010901A3 Antimicrobial histone h1 compositions, kits, and methods of use thereof |
| 08/09/2001 | WO2001010834A9 Antibacterial agents |
| 08/09/2001 | WO2001007066A3 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 08/09/2001 | WO2001007027A3 Pyrimidine derivatives for the treatment of viral diseases |
| 08/09/2001 | WO2001004318A3 Myxoma virus genes for immune modulation |
| 08/09/2001 | WO2001004316A3 Antigenic meningococcal peptides |
| 08/09/2001 | WO2001003664B1 Stabilized ascorbic acid, composition, and method of use |
| 08/09/2001 | WO2000078272A3 Guerbet alcohols |
| 08/09/2001 | WO2000076487A3 Use of paclitaxel and steriod derivatives as aromatase inhibitors for the treatment of cancer |
| 08/09/2001 | WO2000076452A3 Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative |
| 08/09/2001 | WO2000075144A8 Peroxynitrite decomposition catalysts and methods of use thereof |
| 08/09/2001 | WO2000074729A3 Alpha or beta emitters to fragments in radioimmunotherapy |
| 08/09/2001 | WO2000074646A3 Novel liposomal vector complexes and their use in gene therapy |
| 08/09/2001 | WO2000071511A3 INHIBITORS OF FACTOR Xa |
| 08/09/2001 | WO2000071506A3 Naphthalene ureas as glucose uptake enhancers |
| 08/09/2001 | WO2000069895A3 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins |
| 08/09/2001 | WO2000069257A3 Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
| 08/09/2001 | WO2000067740A3 Aminoguanidine for treating glaucomatous optic neuropathy |
| 08/09/2001 | WO2000066173A3 Targeting of infectious agents bearing host cell proteins |
| 08/09/2001 | WO2000066105A9 Treatment of epilepsy with imino sugars |
| 08/09/2001 | WO2000066100A3 2r,4s-hydroxyitraconazole isomers |
| 08/09/2001 | WO2000066095A3 Use of estrone derivatives as antitumour agents |
| 08/09/2001 | WO2000066094A3 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents |
| 08/09/2001 | WO2000064456A3 Substitution infusion fluid and citrate anticoagulation |
| 08/09/2001 | WO2000062813A3 Cationic peg-lipids and methods of use |
| 08/09/2001 | WO2000061729A3 Regulation of the expression of transcriptional repressor genes using nucleic acid molecules |
| 08/09/2001 | WO2000059878A3 INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF |
| 08/09/2001 | WO2000057862A3 Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases |
| 08/09/2001 | WO2000055072A3 Aerosol metering valve |
| 08/09/2001 | WO2000053208A3 Small molecules having glp-2 like activity |
| 08/09/2001 | WO2000047554A3 INHIBITORS OF FACTOR Xa |
| 08/09/2001 | WO2000045795A3 Topical sprays comprising a film forming composition |
| 08/09/2001 | WO2000037643A3 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| 08/09/2001 | WO2000015202A3 Topical application products |
| 08/09/2001 | WO2000005224A3 Heterocyclic derivatives and their use as integrin inhibitor |
| 08/09/2001 | US20010012938 Spine distraction implant |
| 08/09/2001 | US20010012896 Crystallization, heating |
| 08/09/2001 | US20010012895 Therapy for hair loss in mammals; drug resistance; nervous system disorders |
| 08/09/2001 | US20010012889 36 human secreted proteins |
| 08/09/2001 | US20010012858 Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| 08/09/2001 | US20010012857 Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| 08/09/2001 | US20010012856 Compositions and methods for the treatment of anorectal disorders |
| 08/09/2001 | US20010012855 Administering to the mammal an effective amount of a venlafaxine derivative to treat obesity, panic disorder, post-traumatic stress disorder, attention deficit disorder, Gilles de la Tourette syndrome, bulimia nervosa, anxiety etc. |
| 08/09/2001 | US20010012854 Administering to the patient a diamide compound to induce apoptosis in tumor cells |
| 08/09/2001 | US20010012853 Methods for regulating skin appearance |
| 08/09/2001 | US20010012852 Oxetanone compounds covelently linked with a polysacchride; lipase inhibitor |
| 08/09/2001 | US20010012851 A carbamate, carbonate or carboxasulfide containing oxindole compound used for treating osteroarthritis, an inflammatory disease or degenerative joint disease without causing side effect |
| 08/09/2001 | US20010012850 Administering to a human or an animal with undesired angiogenesis an effective amount of 2-phthalimidinoglutaric acid (EM-138) |
| 08/09/2001 | US20010012849 Pharmaceutical composition and method for treatment of inflammation |
| 08/09/2001 | US20010012848 An indane-like compounds which can be useful for treating psychosis and other conditions associated with modulation of a muscarinic receptor |
| 08/09/2001 | US20010012847 Methods and devices for providing prolonged drug therapy |
| 08/09/2001 | US20010012845 Adminstering an E-type prostaglandin ligand and a cyclooxygenase-2 enzyme selective inhibitor compound in combination with a carrier to treat inflammation |
| 08/09/2001 | US20010012844 Quinazoline, nitrothiazole and indolinone based hydrophobic formulations for oral administration for treating cell proliferation disorder in a mammal |
| 08/09/2001 | US20010012842 Lomefloxacin, or a pharmaceutically acceptable salt free of its (R)-stereoismomer is useful for treating infections, but insufficient to cause adverse effect associated with administration of racemic lomefloxacin |
| 08/09/2001 | US20010012840 Topical transdermal treatments |
| 08/09/2001 | US20010012839 Administering to a patient an effective amount of an aryl amide containing compound, which binds irreversibly to the androgen receptor of the prostate cancer patient |
| 08/09/2001 | US20010012838 Methods for inhibiting bone resorption |
| 08/09/2001 | US20010012837 Anti-ulcer composition |
| 08/09/2001 | US20010012835 Transducing a target cell with a nucleic acid sequence encoding a dCK protein (deoxycytidine kinase) having phosphorylation activity operably linked to a promoter |
| 08/09/2001 | US20010012834 Treating pulmonary disorders with gaseous agent causing repletion of GSNO |
| 08/09/2001 | US20010012627 Neurotransmitter transporter SC6 |
| 08/09/2001 | US20010012626 Polynucleotides encoding Presenilin 1 (PS1); diagnosing a patient having an increased likelihood of contracting Alzheimer's disease |
| 08/09/2001 | US20010012621 Determining the expression of lysyl oxidase, the expression of lysyl oxidase indicating that the compound is capable of suppressing ras functions |
| 08/09/2001 | US20010012521 Concurrent melting |
| 08/09/2001 | US20010012518 Oral dosage |
| 08/09/2001 | US20010012511 Sterile barrier |
| 08/09/2001 | EP1143950A3 Topical application products |
| 08/09/2001 | DE19953517C1 Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation Use of treosulphan for conditioning of patients before Knochemarktransplantation or blood stem cell transplantation |